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Abstract
Background: Long-acting muscarinic antagonist/long-acting β2-agonist combinations are recommended for patients
whose chronic obstructive pulmonary disease (COPD) is not managed with monotherapy. We assessed the efficacy
and safety of glycopyrrolate (GP)/formoterol fumarate (FF) fixed-dose combination delivered via a Co-Suspension™
Delivery Technology-based metered dose inhaler (MDI) (GFF MDI).
Methods: This was a Phase IIb randomized, multicenter, placebo-controlled, double-blind, chronic-dosing (7 days),
crossover study in patients with moderate-to-very severe COPD (NCT01085045). Treatments included GFF MDI twice
daily (BID) (GP/FF 72/9.6 μg or 36/9.6 μg), GP MDI 36 μg BID, FF MDI 7.2 and 9.6 μg BID, placebo MDI, and open-label
formoterol dry powder inhaler (FF DPI) 12 μg BID or tiotropium DPI 18 μg once daily. The primary endpoint was forced
expiratory volume in 1 s area under the curve from 0 to 12 h (FEV1 AUC0–12) on Day 7 relative to baseline FEV1.
Secondary endpoints included pharmacokinetics and safety.
Results: GFF MDI 72/9.6 μg or 36/9.6 μg led to statistically significant improvements in FEV1 AUC0–12 after 7 days’
treatment versus monocomponent MDIs, placebo MDI, tiotropium, or FF DPI (p≤ 0.0002). GFF MDI 36/9.6 μg was non-
inferior to GFF MDI 72/9.6 μg and monocomponent MDIs were non-inferior to open-label comparators. Pharmacokinetic
results showed glycopyrrolate and formoterol exposure were decreased following administration via fixed-dose
combination versus monocomponent MDIs; however, this was not clinically meaningful. GFF MDI was well tolerated.
Conclusions: GFF MDI 72/9.6 μg and 36/9.6 μg BID improve lung function and are well tolerated in patients with
moderate-to-very severe COPD.
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Background
Concurrent use of long-acting muscarinic antagonist
(LAMA) and long-acting β2-agonist (LABA) therapy has
been shown to maximize the bronchodilator response [1],
and dual LAMA/LABA combination therapy is now rec-
ommended as an alternative option for patients whose
chronic obstructive pulmonary disease (COPD) is not well
managed with bronchodilator monotherapy [2, 3]. In
addition to providing improvements in airflow limitation
and symptom control, dual bronchodilator therapy reduces
the risk of adverse effects that may be associated with
increased dosages of a single bronchodilator [1]. The use of
a fixed-dose combination (FDC), in which the two agents
are combined in a single device, may improve adherence,
leading to improved outcomes and reduced costs [4, 5].
There are currently options for both once-daily (QD) and
twice-daily (BID) dosing of LAMA/LABA FDCs [6], with
some evidence suggesting that BID dosing may be prefera-
ble for patients who experience night-time symptoms [7].
However, choice of delivery device has been limited to
LAMA/LABA FDCs delivered by dry powder inhalers
(DPIs) or Soft Mist™ devices. Thus there is an opportunity
to expand patient choice by developing a metered dose in-
haler (MDI) formulation-based LAMA/LABA FDC.
A Co-Suspension™ Delivery Technology has been
developed to overcome the variability and instability
associated with drug delivery via traditional hydro-
fluoroalkane propellant-based MDI devices. This tech-
nology uses a novel formulation technique in which
active-agent particles (typically in the form of micronized
drug crystals) form strong and non-specific associations
within the propellant with specially engineered porous mi-
croparticles, made from distearoylphosphatidylcholine
and calcium chloride. These formulations possess excel-
lent stability and dose uniformity, and allow simultaneous
delivery of multiple drugs from one MDI without one
drug affecting the delivery of the others, and maintain
consistency of dose and aerosol properties between mono-
therapies and their combinations [8].
This Phase IIb study investigated the efficacy and safety
of a LAMA/LABA FDC MDI, GFF MDI, containing glyco-
pyrrolate (GP; equivalent to the bromide salt, glycopyrro-
nium bromide) and formoterol fumarate (FF) formulated
using the Co-Suspension delivery technology, using the
dose of glycopyrrolate identified in a dose-response study
in patients with moderate-to-severe COPD [9]. Earlier
Phase I/IIa studies evaluated the efficacy and safety of the
individual components, using a previous formulation of
phospholipid porous particles [10, 11].
The primary objective of this two-part study was to assess
lung function, specifically the improvement in forced ex-
piratory volume in 1 s (FEV1) area under curve (AUC) from
0 to 12 h post-dose (FEV1 AUC0–12). Firstly to assess im-
provements in FEV1 AUC0–12 with GFF MDI 72/9.6 μg or
36/9.6 μg BID compared with individual component MDIs,
placebo MDI (suspension of porous microparticles only), or
the open-label comparators FF DPI and tiotropium bromide
DPI in patients with COPD. Secondly, to assess improve-
ments in FEV1 AUC0–12 reported with FF 9.6 μg MDI ver-
sus placebo MDI in patients with COPD. The safety profiles
of GFF MDI and FF MDI, as well as the pharmacokinetic
(PK) profiles of both glycopyrrolate and formoterol after
chronic administration of GFF MDI, were also investigated.
Methods
Patients
Patients were 40–80 years of age with a diagnosis of
COPD and were current or former smokers, with a
smoking history of at least 10 pack-years. Key lung function
criteria were: pre- and post-bronchodilator FEV1/forced
vital capacity (FVC) ratio <0.7; post-bronchodilator
FEV1 ≥750 mL, and ≥30% and <80% of the predicted value
at screening; and pre-bronchodilator FEV1 ≤ 80% at base-
line. Key exclusion criteria were: pregnancy or lactation; re-
spiratory disease other than COPD; poorly managed COPD
that had required hospitalization within 3 months of
screening, or treatment with corticosteroids or antibiotics
within 6 weeks of screening. In addition, patients who did
not meet American Thoracic Society criteria for acceptable
spirometry were excluded. Patients provided informed
consent before undergoing any screening assessments.
Study design
This was a Phase IIb randomized, multicenter, placebo-
controlled, double-blind, chronic dosing (7 days), four-
period, eight-treatment, incomplete-block, crossover
study, conducted in two parts in the USA, Australia, and
New Zealand (NCT01085045). Patients recruited to Part
A were not eligible for Part B. The design of the study is
depicted in Additional file 1: Figure S1.
Part A was a four-period, eight-treatment, incomplete-
block crossover study, designed to evaluate eight treatments:
(i) GFF MDI 72/9.6 μg BID; (ii) GFF MDI 36/9.6 μg BID;
(iii) GP MDI 36 μg BID; (iv) FF MDI 9.6 μg BID; (v) FF
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MDI 7.2 μg BID; (vi) placebo MDI BID; (vii) FF DPI 12 μg
BID; and (viii) tiotropium DPI 18 μg QD. In this report, GP
was expressed as glycopyrrolate (also known as glycopyrro-
nium bromide) for which ex-actuator doses of 36 μg and
72 μg are equivalent to glycopyrronium (active moiety)
28.8 μg and 57.6 μg, respectively. Similarly, FF was expressed
as formoterol fumarate, for which the dose of 9.6 μg (ex-ac-
tuator) is equivalent to formoterol fumarate dihydrate 10 μg.
Each patient received four of eight possible treatments. A
given treatment sequence included a GP MDI or an FF
MDI component in no more than two treatment periods,
whether administered as an FDC or as a single agent. Six
combinations of four treatments were chosen for the study
and then 48 treatment sequences created. Patients were
randomized to one of the 48 treatment sequences which
were generated centrally using an Interactive Web-based
Response System based on Williams Square layouts.
Part B was a four-period, four-treatment, full-crossover
study designed to evaluate: (i) FF MDI 9.6 μg BID; (ii) FF
MDI 7.2 μg BID; (iii) placebo MDI BID; and (iv) FF DPI
12 μg BID. Patients were randomized to one of 24 possible
treatment sequences, which were generated in the same
way as Part A.
Patients administered each of their four assigned treat-
ments for 1 week, followed by a 7- to 21-day washout
period between treatments. All inhalers were dispensed in
a blinded manner, with the exception of FF DPI and
tiotropium DPI, which were provided open-label. The first
dose of study drug was administered at the clinic under
the supervision of a study coordinator (patients had been
assessed previously for correct use of the MDI by study
staff when using an albuterol MDI for the bronchodilator
reversibility assessment). Self-administration continued at
home. Each dose comprised two MDI actuations. Patients
used their study drug BID for 1 week. FF DPI and open-
label tiotropium DPI were administered for 7 days,
according to the manufacturer’s instructions.
This study was conducted in accordance with Inter-
national Conference on Harmonization guidelines, the
Declaration of Helsinki and the US Code of Federal
Regulations. The protocol, its amendments and patient
informed consent form were approved by an Independent
Ethics Committee or Institutional Review Board.
Efficacy endpoints
In both parts of the study, the primary endpoint was
FEV1 AUC0–12 on Day 7 relative to baseline FEV1. In
Part A, there were two primary comparisons: (i) GFF
MDI 72/9.6 μg BID versus GP MDI 36 μg BID and (ii)
GFF MDI 72/9.6 μg BID versus FF MDI 9.6 μg BID. To
demonstrate efficacy for GFF MDI, superiority to both
monocomponent MDIs was required. In Part B, the pri-
mary endpoint was based on the comparison of FF MDI
9.6 μg BID with placebo MDI BID.
The secondary efficacy endpoints of the study included
measurements on both Day 1 and Day 7: peak change from
baseline in FEV1, time to onset of action (≥10% improve-
ment in FEV1 relative to baseline), proportion of patients
achieving ≥12% improvement in FEV1 relative to baseline,
peak change from baseline in inspiratory capacity (IC) and
change in morning pre-dose trough FEV1 and IC. An ex-
ploratory endpoint included change from baseline in FVC.
These endpoints provided additional information on the
dose-response of bronchodilator effects on lung function
for GFF MDI and FF MDI by exploring two doses for each
versus active comparators and placebo MDI: GFF MDI 72/
9.6 μg and 36/9.6 μg, and FF MDI 7.2 μg and 9.6 μg.
Pharmacokinetics
PK parameters were derived from the plasma concentra-
tions of glycopyrrolate and formoterol fumarate obtained
on approximately Day 7 (Day 7 ± 2) of each treatment
regimen during Study Parts A and B. In Part A, the PK
profiles of glycopyrrolate and formoterol after chronic
administration of GFF MDI were compared with those
after chronic administration of the monocomponent
MDIs. In Part B, the PK profile of formoterol after chronic
administration of two dose levels of FF MDI was com-
pared with those after chronic administration of FF DPI.
PK samples were collected at pre-dose, at 2, 6 and 20 min,
and at 1, 2, 4, 8, 10 and 12 h post-dose. PK analyses were
performed by Pharsight Inc using a validated version of
WinNonlin® Enterprise (Version 5.2).
Safety evaluations
In addition to monitoring adverse events (AEs) and ser-
ious AEs (SAEs), the following safety evaluations were
performed: 12-lead electrocardiogram (ECG), vital signs,
physical examination, clinical laboratory tests, and evalu-
ation for symptoms of AEs of interest including dry
mouth, tremor and paradoxical bronchospasm.
Statistical analysis
Data processing, data screening, descriptive reporting
and analysis of the efficacy and safety data were
performed using SAS Version 9.2 (SAS Institute, Inc.,
Cary, NC). The PK data were analyzed using WinNon
Lin Version 5.2 (Pharsight Corp., USA). PK graphs were
prepared using SigmaPlot for Windows Version 9.01
(Systatsoftware, Inc., San Jose, CA). Power calculations
were performed using R software. Further details of
statistical methods and analysis are detailed in the
Additional file 1.
The primary efficacy analysis was based on a modified
intent-to treat (mITT) population, defined as patients who
completed at least two treatment periods up to at least 2 h
post-dose on Day 7 (with no more than one missing data
point from the 15-min to the 2-h post-dose timepoint,
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inclusive); patients whose baseline FEV1 at Visits 4, 6 and
8 was not within 15% of baseline FEV1 at Visit 2 (reprodu-
cibility criteria) were also excluded from the mITT popu-
lation. A separate population, PK-mITT, was defined for
use in the PK analyses.
Data from Part A and Part B were combined for analysis
using a linear mixed-effects model of the primary endpoint
FEV1 AUC0–12 (baseline FEV1 was included as a covariate).
The AUC was calculated using trapezoidal integration on
the available timepoints. Superiority testing was performed
using a two-sided 0.05 level of significance; non-inferiority
testing was performed using a 0.025 level of significance
based on a one-sided confidence interval (CI). The pre-
defined non-inferiority margin for continuous spirometry
variables was 100 mL, selected on the basis that it is the
minimally clinically significant difference, defined as the
change in FEV1 that can be perceived by the patient [12].
As such, non-inferiority was only confirmed for a treatment
group if the relevant bound of the two-sided 95% CI for the
difference was above−100 mL or below 100 mL. Mean
changes from baseline in FEV1 were provided with 95% CI
to support any conclusions of non-inferiority.
Sample size calculations
Calculations to determine adequate sample size were based
on the primary endpoint, FEV1 AUC0–12. For superiority
testing of spirometry parameters, a difference of 100 mL
was the pre-defined minimally clinically significant differ-
ence to be observed in FEV1 AUC0–12. Combined data
from Part A and Part B gave the study the power of
approximately 82–95% to detect the minimally clinically
significant difference in FEV1 AUC0–12 between the treat-
ment comparisons of interest.
Role of the funding source
The funder of the study was involved in study design, data
collection, data analysis, data interpretation and writing of
the report. All authors had full access to all the data in the
study and the corresponding author had the final responsi-
bility for the decision to submit for publication. No restric-
tions were placed on authors regarding the statements
made in the manuscript.
Results
Patient disposition
A total of 169 patients were screened and 122 were ran-
domized between 24 March 2010 and 28 October 2010 to
receive treatment at sites in Australia, New Zealand and
the USA. Following review of data from four sentinel
patients, 118 patients were randomized: 68 patients into
Part A and 50 patients into Part B (Fig. 1). All 118 patients
received at least one dose of study drug and were included
Fig. 1 Patient disposition. In Part A, patients were randomized to receive any of the eight treatments in each of the four periods of the study in an
incomplete block crossover design. In Part B, patients were randomized to receive all three formoterol doses and placebo in each of the four periods
of the study in a full crossover design. aFive patients met multiple criteria for exclusion from randomization (not meeting inclusion criteria and/or
meeting exclusion criteria). bPatients randomized to treatment, who received at least one dose of study drug. cPatients who completed at least two
treatment periods with at least 2 h of post-dose data on Day 7, with no more than one missing data-point from 15 min to 2 h post-dose, inclusive.
COPD, chronic obstructive pulmonary disease; CT, computed tomography; ITT, intent-to-treat; LRTI, lower respiratory tract infection; mITT, modified ITT
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in the ITT population and 104 patients (88.1%) were
included in the mITT population. Major reasons for exclu-
sion from the mITT population were: (i) patient did not
complete at least two treatment periods up to at least 2 h
post-dose on Day 7 (Part A, 10.3% of patients and Part B,
14.0% of patients), and (ii) patient failed reproducibility
criteria or had missing data on Day 7 (maximum of 3.4%
patients in any one period of the study). There were 82
patients (69.5%) included in the per-protocol population
(patients who completed all four treatment periods). The
majority of patients (80.5 to 96.2% across treatment groups)
received 80 to 100% of their assigned treatment regimen.
Baseline characteristics
Patients’ baseline and demographic characteristics are shown
in Table 1 (mITT population). Briefly, the mean (± standard
deviation [SD]) duration of patients’ history of COPD was 7.7
(±5.9) years; the mean post-bronchodilator FEV1 was 50.8
(±12.7) % of predicted; and the mean FEV1 bronchodilator
reversibility was 16.9 (±14.9) %. Overall, 52.9% (55/104) of
patients had moderate COPD, 44.2% (46/104) had severe
COPD and 2.9% (3/104) had very severe COPD.
FEV1 AUC0–12 on Day 7
Figure 2a shows the least squares mean (LSM) change
from baseline in FEV1 over 12 h on Day 7. All active treat-
ments were superior to placebo MDI for FEV1 AUC0–12
on Day 7 (p < 0.0001) (Figure 2b). GFF MDI 36/9.6 μg was
non-inferior to GFF MDI 72/9.6 μg in FEV1 AUC0–12 on
Day 7 since the upper bound of the CI was <100 mL (LSM
difference between treatments = 0.008 L; 95% CI = −0.039,
0.054 L). GFF MDI 72/9.6 μg and GFF MDI 36/9.6 μg each
demonstrated superior bronchodilation of 101 to 124 mL
compared with their individual component MDIs, GP
MDI 36 μg, FF MDI 9.6 μg and FF MDI 7.2 μg, as well as
superior bronchodilation compared with the open-label
comparators FF DPI and tiotropium DPI (p ≤ 0.0002)
for FEV1 AUC0–12 on Day 7 (Table 2). GP MDI 36 μg,
Table 1 Baseline demographics (mITT population)
Parameter GFF MDI GP MDI 36 μg
(N = 41)
Open-label
tiotropium
18 μg (N = 58)
FF MDI Placebo MDI
(N = 52)
Open-label
FFa DPI 12 μg
(N = 55)
72/9.6 μg
(N = 41)
36/9.6 μg
(N = 43)
9.6 μg
(N = 64)
7.2 μg
(N = 64)
Age, years
Mean (SD) 62.4 (9.4) 63.3 (8.3) 66.3 (6.1) 64.1 (7.9) 63.4 (8.9) 63.6 (8.9) 62.8 (9.6) 60.6 (9.0)
Gender, n (%)
Male 25 (61.0) 24 (55.8) 23 (56.1) 34 (58.6) 34 (53.1) 36 (56.3) 29 (55.8) 34 (61.8)
Race, n (%)
Black/African 0 0 0 0 3 (4.7) 3 (4.7) 3 (5.8) 3 (5.5)
White 39 (95.1) 42 (97.7) 41 (100) 57 (98.3) 61 (95.3) 61 (95.3) 48 (92.3) 52 (94.5)
Australia/New Zealand
(indigenous)
2 (4.9) 1 (2.3) 0 1 (1.7) 0 0 1 (1.9) 0
Smoking status, n (%)
Current 16 (39.0) 18 (41.9) 15 (36.6) 24 (41.4) 29 (45.3) 28 (43.8) 24 (46.2) 25 (45.5)
Former 25 (61.0) 25 (58.1) 26 (63.4) 34 (58.6) 35 (54.7) 36 (56.3) 28 (53.8) 30 (54.5)
Duration of COPD, years
Mean (SD) 7.6 (7.3)b 6.2 (5.4)c 7.8 (6.2)b 7.4 (6.7)d 8.6 (6.1)e 7.7 (4.4)f 8.3 (5.2)g 7.3 (4.3)h
Mean % predicted FEV1 (SD)
Pre-bronchodilator 44.1 (13.9)b 46.8 (14.1)c 45.8 (13.5)b 44.9 (13.9)d 44.7 (12.6)e 43.9 (12.0)f 43.7 (11.6)g 44.0 (13.3)h
Post-bronchodilator 50.6 (13.0)b 53.0 (13.1)c 51.5 (13.3)b 51.3 (13.4)d 51.4 (12.5)e 50.2 (12.6)f 51.1 (12.4)g 50.9 (12.9)h
Mean FEV1, L (SD)
Pre-bronchodilator 1.33 (0.48)b 1.38 (0.47)c 1.30 (0.41)b 1.33 (0.47)d 1.29 (0.43)e 1.28 (0.40)f 1.30 (0.41)g 1.35 (0.46)h
Post-bronchodilator 1.52 (0.47)b 1.56 (0.47)c 1.46 (0.40)b 1.51 (0.46)d 1.49 (0.46)e 1.47 (0.43)f 1.52 (0.47)g 1.56 (0.48)h
FEV1 bronchodilator reversibility, L (SD)
i
Mean (SD) 17.8 (16.3)b 16.3 (17.2)c 14.2 (14.5)b 17.1 (16.2)d 17.5 (14.7)e 15.9 (12.7)f 18.6 (12.9)g 18.5 (15.5)h
aForadil® Aerolizer®; bn = 38; cn = 39; dn = 56; en = 58; fn = 63; gn = 45; hn = 54; ipercentage change from pre-albuterol at 30 min post-albuterol for FEV1
% = 100 × n/N, where n = number of patients in category and N = number of patients in the group
Duration of COPD = (date of first dose of study treatment in the study – COPD onset date)/365.25
Data from four sentinel patients were included in the mITT population in the analyses of demographic and baseline characteristics only
COPD chronic obstructive pulmonary disease, DPI dry powder inhaler, FEV1 forced expiratory volume in 1 s, FF formoterol fumarate, GFF glycopyrrolate/formoterol
fumarate, GP glycopyrrolate, MDI metered dose inhaler, mITT modified intent-to-treat, SD standard deviation
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Fig. 2 FEV1 AUC0–12 on Day 7 efficacy endpoint. a LSM change (95% CI) in FEV1 over 0–12 h on Day 7 by treatment; b LSM (95% CI) FEV1 AUC0–12
difference from placebo on Day 7 by treatment (mITT population). aForadil® Aerolizer®. bLSM allows for any imbalances in baseline covariates that relate
to responses to be adjusted for in order to avoid bias in treatment effect estimates. AUC0–12, area under the curve from 0 to 12 h post-dose; DPI, dry
powder inhaler; FEV1, forced expiratory volume in 1 s; FF, formoterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; LSM, least
squares mean; MDI, metered dose inhaler; mITT, modified intent-to-treat
Table 2 FEV1 AUC0–12 at Day 7: GFF MDI 72/9.6 μg and 36/9.6 μg comparisons (mITT population)
LSM treatment differences for GFF MDI in FEV1 AUC0–12 at Day 7
GFF MDI GP MDI 36 μg Open-label
tiotropium
18 μg
FF MDI Placebo MDI Open-label FFa
DPI 12 μgComparator 72/9.6 μg 36/9.6 μg 9.6 μg 7.2 μg
GFF MDI 72/9.6 μg
LSMb difference (SE), L NA 0.008 (0.0236) 0.109 (0.0250)† 0.103 (0.0216)† 0.116 (0.0245)† 0.124 (0.0237)† 0.298 (0.0261)† 0.101 (0.0241)†
95% CI −0.039, 0.054 0.059, 0.158c 0.060, 0.145 0.068, 0.165 0.078, 0.171 0.247, 0.349 0.053, 0.148
GFF MDI 36/9.6 μg
LSMb difference (SE), L See above NA 0.101 (0.0245)† 0.095 (0.0213)† 0.109 (0.0242)† 0.116 (0.0236)† 0.290 (0.0261)† 0.093 (0.0241)***
95% CI 0.053, 0.149 0.053, 0.137 0.061, 0.156 0.070, 0.163 0.239, 0.342 0.045, 0.140
***p < 0.001; †p < 0.0001
aForadil® Aerolizer®; bLSM allows for any imbalances in baseline covariates that relate to responses to be adjusted for in order to avoid bias in treatment effect
estimates; cnon-inferiority comparison
CI, confidence interval; DPI, dry powder inhaler; FEV1 AUC0–12, forced expiratory volume in 1 s area under the curve from 0 to 12 h post-dose; FF, formoterol fumarate; GFF,
glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; LSM, least squares mean; MDI, metered dose inhaler; mITT, modified intent-to-treat; NA, not available; SE, standard error
Reisner et al. Respiratory Research  (2017) 18:8 Page 6 of 13
Table 3 Secondary efficacy endpoints: Days 1 and 7 – GFF MDI 72/9.6 μg and GFF MDI 36/9.6 μg comparisons (mITT population)
Comparator Treatment differences for GFF MDI comparisons
GP MDI 36 μg Open-label
tiotropium 18 μg
FF MDI Placebo MDI Open-label
FFa DPI 12 μg9.6 μg 7.2 μg
DAY 7
Change from baseline in morning pre-dose trough FEV1, L
GFF MDI 72/9.6 μg
LSMb difference (SE) 0.0960 (0.0280)*** 0.096 (0.0247)† 0.129 (0.0278)† 0.120 (0.0271)† 0.234 (0.0302)† 0.091 (0.0277)**
GFF MDI 36/9.6 μg
LSMb difference (SE) 0.073 (0.0273)** 0.073 (0.0245)** 0.106 (0.0274)† 0.097 (0.0270)*** 0.211 (0.0300)† 0.068 (0.0275)*
Peak change from baseline in FEV1, L
GFF MDI 72/9.6 μg
LSMb difference (SE) 0.125 (0.0282)† 0.140 (0.0248)† 0.101 (0.0279)*** 0.108 (0.0271)† 0.342 (0.0300)† 0.082 (0.0278)**
GFF MDI 36/9.6 μg
LSMb difference (SE) 0.127 (0.0273)† 0.141 (0.0245)† 0.103 (0.0273)*** 0.110 (0.0268)† 0.344 (0.0298)† 0.083 (0.0276)**
Change from baseline in morning pre-dose trough IC, L
GFF MDI 72/9.6 μg
LSMb difference (SE) 0.083 (0.0445) 0.090 (0.0399)* 0.156 (0.0452)*** 0.110 (0.0436)* 0.255 (0.0483)† 0.096 (0.0447)*
GFF MDI 36/9.6 μg
LSMb difference (SE) 0.098 (0.0445)* 0.105 (0.0387)** 0.172 (0.0433)† 0.126 (0.0428)** 0.271 (0.0471)† 0.111 (0.0434)*
Peak change from baseline in IC, L
GFF MDI 72/9.6 μg
LSMb difference (SE) 0.078 (0.0532) 0.095 (0.0470)* 0.050 (0.0529) 0.033 (0.0513) 0.265 (0.0572)† 0.016 (0.0527)
GFF MDI 36/9.6 μg
LSMb difference (SE) 0.107 (0.0513)* 0.124 (0.0461)** 0.078 (0.0513) 0.062 (0.0503) 0.293 (0.0559)† 0.045 (0.0518)
DAY 1
Peak change from baseline in FEV1, L
GFF MDI 72/9.6 μg
LSMb difference (SE) 0.081 (0.0309)** 0.104 (0.0268)† 0.062 (0.0307)* 0.060 (0.0297)* 0.265 (0.0328)† 0.072 (0.0306)*
GFF MDI 36/9.6 μg
LSMb difference (SE) 0.068 (0.300)* 0.090 (0.0266)*** 0.048 (0.0300) 0.046 (0.0293) 0.251 (0.0326)† 0.058 (0.0303)
Peak change from baseline in IC, L
GFF MDI 72/9.6 μg
LSMb difference (SE) 0.065 (0.0567) 0.149 (0.0493)** 0.134 (0.0564)* 0.144 (0.0547)** 0.412 (0.0607)† 0.121 (0.0561)*
GFF MDI 36/9.6 μg
LSMb difference (SE) −0.019 (0.0555) 0.065 (0.0491) 0.050 (0.0554) 0.060 (0.0542) 0.328 (0.0602)† 0.037 (0.0557)
Time to onset of action, hazard ratioc
GFF MDI 72/9.6 μg
HR 1.399* 1.754*** 0.980 1.150 3.475† 0.971
95% CI 1.038, 1.884 1.300, 2.367 0.746, 1.289 0.904, 1.465 2.095, 5.765 0.713, 1.321
GFF MDI 36/9.6 μg
HR 1.323 1.695*** 0.888 1.062 3.358† 0.878
95% CI 0.936, 1.870 1.275, 2.253 0.671, 1.175 0.0806, 1.400 2.091, 5.391 0.660, 1.169
*p < 0.05; **p < 0.01; ***p < 0.001; †p ≤ 0.0001
aForadil® Aerolizer®; bLSM allows for any imbalances in baseline covariates that relate to responses to be adjusted for in order to avoid bias in treatment effect
estimates; ca hazard ratio of 1.399 signifies a 39.9% higher probability of onset of action at any time point post-dose
CI confidence interval, DPI dry powder inhaler, FEV1 forced expiratory volume in 1 s, FF formoterol fumarate, GFF glycopyrrolate/formoterol fumarate, GP
glycopyrrolate, HR hazard ratio, IC inspiratory capacity, LSM least squares mean, MDI metered dose inhaler, mITT modified intent-to-treat, SE standard error
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demonstrated non-inferiority to the LAMA comparator
open-label tiotropium DPI for FEV1 AUC0–12 on Day 7
(LSM difference between treatments = −0.006 L; 95%
CI = −0.049, 0.038 L). Both doses of FF MDI (7.2 and
9.6 μg) demonstrated non-inferiority to the open-label
comparator FF DPI (Table 2).
Secondary endpoints
All active treatments were superior to placebo MDI for the
lung function secondary endpoints (peak change from base-
line in FEV1; time to onset of action on Day 1 [≥10%
improvement in FEV1 relative to baseline]; peak change
from baseline FEV1 and change from baseline in morning
pre-dose trough FEV1 and 12-h post-dose trough FEV1;
peak change from baseline in IC, change from baseline in
morning pre-dose trough IC and 12-h post-dose trough IC;
mean daily peak flow readings) on Days 1 and 7 (p ≤
0.0056). The percentage of patients achieving ≥12% im-
provement in FEV1 was 86.8% (GFF MDI 72/9.6 μg), 87.2%
(GFF MDI 36/9.6 μg), 73.7% (GP MDI 36 μg) 66.1% (open-
label tiotropium DPI 18 μg), 84.5% (FF MDI 9.6 μg), 82.5%
(FF MDI 7.2 μg), 40.0% (placebo MDI) and 85.2% (FF DPI
12 μg). Inferential comparisons of the percentage of patients
achieving ≥12% improvement in FEV1 were not possible for
several comparisons due to the limited number of patients
(≤5) receiving each pair of treatments. However, numerical
benefits were observed for all active treatments compared
to placebo. GFF MDI 36/9.6 μg demonstrated non-
inferiority to GFF MDI 72/9.6 μg (Table 3; Additional file 1).
At Day 7, GFF MDI 72/9.6 μg and GFF MDI 36/9.6 μg
demonstrated superiority to each monocomponent MDI
and to open-label FF DPI and tiotropium for morning
peak FEV1, peak change in FEV1, and morning pre-
dose trough IC (Table 3; Additional file 1). FF MDI
7.2 μg and FF MDI 9.6 μg were both non-inferior to
FF DPI, and FF MDI 7.2 μg was non-inferior to FF MDI
9.6 μg in secondary endpoints at Day 7 (Additional file 1).
Exploratory endpoint
All active treatments were superior to placebo (p < 0.0001)
for change from baseline FVC (calculated as AUC0–12) on
Day 7 (Additional file 1: Figure S2). Treatment comparisons
are shown in the Additional file 1.
Safety and tolerability
Most AEs were of mild (32.0%) or moderate (29.5%) inten-
sity. Treatment-emergent AEs (TEAEs) reported in more
than two patients receiving treatment are displayed in
Table 4. The most commonly reported TEAEs were: dry
mouth, headache, tremor, cough and dysphonia (Table 4).
Dry mouth was reported more frequently by patients
receiving GP MDI, GFF MDI, and open-label tiotropium
compared to the other groups, while headache and tremor
were reported more frequently by patients receiving GFF
MDI. No patient in any treatment period reported paradox-
ical bronchospasm. The incidence of TEAEs was similar for
the two doses of GFF MDI (31.7% vs 27.9%).
Table 4 Summary of adverse events (safety population)
GFF MDI GP MDI 36 μg
(N = 41)
Open-label tiotropium
18 μg (N = 58)
FF MDI Placebo MDI
(N = 52)
Open-label
FFa DPI 12 μg
(N = 55)
72/9.6 μg
(N = 41)
36/9.6 μg
(N = 43)
9.6 μg
(N = 64)
7.2 μg
(N = 64)
Patients with at least one AE, n (%) 17 (41.5) 18 (41.9) 11 (26.8) 22 (37.9) 24 (37.5) 16 (25.0) 9 (17.3) 17 (30.9)
Patients with AE related to study
treatment, n (%)
13 (31.7) 12 (27.9) 7 (17.1) 7 (12.1) 7 (10.9) 4 (6.3) 2 (3.8) 7 (12.7)
Patients with SAE, n (%) 0 1 (2.3) 0 2 (3.4) 1 (1.6) 2 (3.1) 0 0
Patients with SAE related to study
treatment, n (%)
0 0 0 0 0 0 0 0
Patients with AE leading to early
withdrawal, n (%)
1 (2.4) 0 1 (2.4) 1 (1.7) 4 (6.3) 3 (4.7) 1 (1.9) 0
Patients with SAE leading to early
withdrawal, n (%)
0 0 0 0 0 2 (3.1) 0 0
TEAEs reported in ≥2 patients in any treatment group
Dry mouth 8 (19.5) 3 (7.0) 5 (12.2) 4 (6.9) 3 (4.7) 2 (3.1) 1 (1.9) 2 (3.6)
Headache 3 (7.3) 4 (9.3) 1 (2.4) 1 (1.7) 1 (1.6) 0 1 (1.9) 2 (3.6)
Tremor 1 (2.4) 5 (11.6) 0 0 0 0 0 0
Cough 0 2 (4.7) 0 1 (1.7) 0 0 0 0
Dysphonia 1 (2.4) 2 (4.7) 0 0 0 0 0 0
%= 100 × n/N: n = no. of patients in the preferred term category for treatment group
aForadil® Aerolizer®
AE adverse event, DPI dry powder inhaler, FF formoterol fumarate, GFF glycopyrrolate/formoterol fumarate, GP glycopyrrolate, MDI metered dose inhaler, SAE
serious adverse event, TEAE treatment-emergent adverse event
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Fig. 3 (See legend on next page.)
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Six SAEs were reported in five patients, none of which
was related to study drug (one patient in the GFF MDI
36/9.6 μg group [ruptured appendix]; two patients in the
open-label tiotropium group [inhaled foreign body; ab-
dominal aortic aneurysm]; one patient in the FF MDI
9.6 μg group [gastritis]; and two patients in the FF MDI
7.2 μg group [COPD exacerbation; atypical chest pain
leading to early withdrawal]). No deaths were reported
in the study.
There were no notable changes in hematology or chem-
istry laboratory values and no clinically significant abnor-
malities in vital signs, ECG, or physical examination.
Pharmacokinetics
Following chronic administration of GFF MDI 36/9.6 μg,
the geometric LSM of glycopyrrolate was approximately
9% (AUC0–12) and 14% (maximum observed plasma
concentration [Cmax]) lower than those observed follow-
ing GP MDI 36 μg (Fig. 3a). In addition, the geometric
LSM for formoterol was approximately 7% (AUC0–12)
and 14% (Cmax) lower than those observed when FF
MDI 9.6 μg was administered alone (Fig. 3b).
Results from an analysis of variance (ANOVA) of the
dose-normalized exposure parameters of formoterol be-
tween the FF MDI 9.6 μg and the FF DPI showed that
90% CIs for the ratios of LSM for the exposure parameters
AUC0–12 and Cmax were within the 80–125% interval,
demonstrating that monocomponent FF MDI 9.6 μg was
bioequivalent to the FF DPI formulation (equivalent to an
FF 10 μg dose), with dose normalization. Furthermore,
ANOVA results based on non-dose-normalized PK
parameters also demonstrated equivalence between FF
MDI and FF DPI (Fig. 3c).
Discussion
This 7-day Phase IIb study of GFF MDI 72/9.6 μg and 36/
9.6 μg BID is the first study to investigate the FDC GFF
MDI formulated using Co-Suspension delivery technology
in patients with COPD. Previous studies have investigated
the dose-response of the individual components delivered
via MDI using Co-Suspension delivery technology [9, 13].
GFF MDI 72/9.6 μg and 36/9.6 μg BID led to statistically
significant and clinically relevant improvement in the
primary endpoint FEV1 AUC0–12 at Day 7 compared
with the monocomponent MDIs and placebo MDI in
patients with moderate-to-very severe COPD and
were well tolerated (p ≤ 0.0001).
It has become established that the combination of a
LAMA and LABA provides benefits in lung function in
patients with COPD over LAMA or LABA monotherapy
in those patients who are not adequately controlled by a
single long-acting bronchodilator. Within this therapeutic
approach, LAMA/LABA FDCs glycopyrrolate/indacaterol,
tiotropium/olodaterol, aclidinium/formoterol, and umecli-
dinium/vilanterol have previously demonstrated lung func-
tion benefits over monocomponents [14–19]. This study
was part of a Phase IIb program including dose-ranging
studies of GFF MDI and monocomponents to define the
optimal doses of the GFF MDI FDC to take forward to
Phase III studies, and utilized non-inferiority testing, based
on the targeted 100 mL minimally clinically significant
difference, as a well-defined and reproducible treatment
effect for trough FEV1 to define therapeutic effect [12]. In
this study, non-inferiority was confirmed between GFF
MDI 72/9.6 μg and 36/9.6 μg, incorporating GP doses at
the higher end of the dose range, and both doses showed
statistically significantly greater FEV1 AUC0–12 at Day 7
versus open-label tiotropium DPI and FF DPI. Notably,
GFF MDI demonstrated superiority to placebo and statisti-
cally significant (GFF MDI 72/9.6 μg) and numerically
greater (GFF MDI 36/9.6 μg) improvements in IC com-
pared with open-label tiotropium DPI. In patients with
COPD, changes in IC reflect changes in hyperinflation and
have shown a higher correlation to patient-focused out-
comes, such as dyspnea with exercise, than other standard
spirometric measurements [20]. Additional information
was gained concerning the monocomponents, whereby the
doses of the two monocomponents, GP and FF,
demonstrated non-inferiority to the open-label active
comparators such that GP MDI 36 μg BID was non-
inferior to open-label tiotropium DPI and both doses
of FF MDI demonstrated non-inferiority to open-label
FF delivered via DPI.
The PK component of the study characterized the sys-
temic exposure of glycopyrrolate and formoterol delivered
as an FDC compared with individual components deliv-
ered using Co-Suspension delivery technology. The find-
ings support the absence of a significant drug-drug
interaction for formoterol and glycopyrrolate following
administration of GFF MDI relative to the individual MDI
formulations. It was also shown that formoterol exposure
(See figure on previous page.)
Fig. 3 Ratio of geometric LSMs and 90% CIs. a GFF MDI 36/9.6 μg versus GP MDI 36 μg (b) GFF MDI 36/9.6 μg versus FF MDI 9.6 μg (c) FF MDI 9.6 μg
versus FF DPI (PK-mITT population). aLSM allows for any imbalances in baseline covariates that relate to responses to be adjusted for in order to avoid
bias in treatment effect estimates. bForadil® Aerolizer®. AUC0–inf, area under the curve from time 0 to infinity; AUC0–12, area under the
curve from 0 to 12 h post-dose; CI, confidence interval; Cmax, maximum observed plasma concentration; DPI, dry powder inhaler; FF, for-
moterol fumarate; GFF, glycopyrrolate/formoterol fumarate; GP, glycopyrrolate; LSM, least squares mean; MDI, metered dose inhaler;
PK-mITT, pharmacokinetic modified intent-to-treat
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(AUC0–12) increases in a dose-proportional manner when
delivered via the MDI and that FF MDI 9.6 μg delivered
by MDI using Co-Suspension delivery technology was bio-
equivalent to FF delivered using DPI, which taken together
endorse the dose of FF MDI 9.6 μg in the FDC.
All treatments were generally well tolerated in this
study. The tolerability and safety profiles observed for
GFF MDI 36/9.6 μg and 72/9.6 μg BID were consistent
with the patient population and drug classes [21]. The
most commonly reported TEAEs (more than two pa-
tients in any treatment group) were dry mouth, head-
ache, tremor, cough and dysphonia in descending order
of incidence.
Whilst the sample size of this first study of GFF deliv-
ered by MDI using novel Co-Suspension delivery tech-
nology was calculated to provide reasonable information
to characterize the response, we recognize that the study
was limited by a relatively small population and enrolled
a lower than anticipated number of patients with very
severe COPD. In addition, the study was only conducted
over 7 days. However, information from this study
guided study design and sample size for subsequent
studies.
GFF MDI will potentially widen treatment options for
patients with COPD by providing LAMA/LABA therapy
in an MDI when other LAMA/LABA FDCs are available
as DPI and soft-mist inhaler devices. Unlike other de-
vices, MDIs are not breath-actuated, consequently, MDIs
may be able to offer patients with quite severe airflow
limitation, who may be unable to breathe deeply enough
to release the medication from a DPI, a more practical
and reliable method of delivery of their medication. The
PKs of GFF MDI support twice-daily administration and
the improvements in lung function demonstrated here
after BID dosing with GFF MDI as maintenance dual-
bronchodilator therapy may provide benefits over QD
dosing, preventing excessive worsening of symptoms
during the night or towards the morning in patients
with this pattern of symptoms [7]. The results of a
patient evaluation survey conducted by Partridge et al.,
and similarly in the ASSESS study, show that patients
with COPD begin to experience worsening symptoms
in the evening through the night-time, with the worst
symptoms, affecting activity and productivity, occurring
in the morning [22, 23]. This is also an area for future
investigation of the effects of GFF MDI on COPD
symptom burden.
Conclusions
Co-Suspension delivery technology allows formulation of
FDCs of different drug classes, at different concentrations,
in a single MDI. GFF MDI 72/9.6 μg and 36/9.6 μg
BID were associated with a similarly greater magni-
tude of effect on FEV1 AUC0–12 at Day 7 compared
with the monocomponent MDIs and placebo MDI in
patients with moderate-to-very severe COPD, which is
likely to be the maximal therapeutic effect. Additional
studies are required to establish the optimal doses of
GP and FF for combination in the FDC GFF MDI.
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change from baseline FVC over time by treatment on Day 7 (mITT
population); Additional Table 1. Secondary efficacy endpoints: Days 1 and
7 – FF 9.6 μg and FF 7.2 μg comparisons (mITT population). (DOCX 466 kb)
Abbreviations
AEs: Adverse events; AUC: Area under curve; BID: Twice daily; CI: Confidence
interval; COPD: Chronic obstructive pulmonary disease; CT: Computed
tomography; DPI: Dry powder inhaler; ECG: Electrocardiogram; FDC: Fixed-
dose combination; FEV1 AUC0–12: Forced expiratory volume in 1 s area under
the curve from 0 to 12 h; FEV1: Forced expiratory volume in 1 s;
FF: Formoterol fumarate; FVC: Forced vital capacity; GFF MDI: Glycopyrrolate/
formoterol fumarate MDI; GP: Glycopyrrolate; HFA: Hydrofluoroalkane;
HR: Hazard ratio; IC: Inspiratory capacity; ITT: Intent-to-treat; LABA: Long-
acting beta agonist; LAMA: Long-acting muscarinic antagonist; LRTI: Lower
respiratory tract infection; LSM: Least squares mean; MDI: Metered dose
inhaler; mITT: Modified intent-to treat; NA: Not available; PK: Pharmacokinetic;
QD: Once-daily; SAEs: Serious adverse events; SD: Standard deviation;
SE: Standard error; TEAEs: Treatment-emergent AEs
Acknowledgements
The authors would like to thank all of the patients and their families, the
team of investigators, research nurses and operations staff involved in this
study. The authors would also like to thank Catherine Stanton, of Complete
Medical Communications, who provided medical writing support under the
direction of the authors, funded by AstraZeneca. The authors would also like
to thank Mervyn Thomas for his work in the statistical design and planning
of this study and Everest Clinical Research, who conducted the statistical
analyses of the study data.
Funding
Pearl Therapeutics Inc., a member of the AstraZeneca Group.
Availability of data and material
All relevant data generated or analyzed during this study are included in this
published article (and its additional information files).
Authors’ contributions
KFR, FJM, JFD, LMF, GTF, SD, CR, CO, PD, ES, TF, MG, SSt, SSp made
substantial contributions to the conception or design of the work reported.
EMK, DQ, CF, SSp participated in the acquisition of reported data. SD, CR, CO,
PD participated in the analysis of reported data. KFR, FJM, JFD, LMF, GTF,
EMK, DQ, CF, SSt, SSp, SD, CR, CO, PD participated in the interpretation of
reported data. All authors contributed to the writing of the report and
participated in the review and interpretation of the data. All authors read
and approved the final report before submission.
Authors’ information
[as per title page].
Co-Suspension™ is a trademark of the AstraZeneca group of companies.
List of principal investigators
JoAnne Marjason, Robyn Huttenmeister, Maria Quartararo, Peter Clyne, Paul
Seale, Philip Thompson, Philip Bardin, Dean Quinn, Andrew Veale, Margaret
Wilsher, Graham Mills, Michael Chia, Charles M. Fogarty, Selwyn Spangenthal,
Edward M. Kerwin, Leonard Dunn.
Reisner et al. Respiratory Research  (2017) 18:8 Page 11 of 13
Competing interests
CR is an employee of Pearl Therapeutics, Inc., a member of the AstraZeneca
Group. LMF has received grants, personal fees and non-financial support from
Almirall, AstraZeneca, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, Laboratori
Guidotti, Merck Sharp & Dohme, Menarini, Novartis and Takeda. He has received
personal fees and non-financial support from Boston Scientific, Mundipharma
and Pearl Therapeutics Inc. He has received personal fees from Bayer, Kyorin
and Zambon. He has received grants from Biofutura Italia, Dompè, Malesci,
Pfizer and Vree Health Italia. EMK has served on advisory boards, speaker panels,
or received travel reimbursement from Amphastar, Boehringer Ingelheim,
Forest, Mylan, Novartis, Pearl Therapeutics Inc. (a member of the AstraZeneca
Group), Sunovion, Teva and Theravance. He has conducted multicenter clinical
trials for ~40 pharmaceutical companies. CF is a consultant and investigator for
Pearl Therapeutics, Inc. SSp has no potential conflicts of interest to disclose. KFR
has received grants from Boehringer Ingelheim, the German Federal Ministry of
Education and Research (BMBF) and Novartis. He has received personal fees
from AstraZeneca, Boehringer Ingelheim, Chiesi, Intermune, Novartis and
Takeda. GTF has received grants and personal fees from AstraZeneca, Boehringer
Ingelheim Novartis, Pearl Therapeutics Inc., Sunovian and Theravance. He has
received grants from Forest. He has received personal fees GlaxoSmithKline, Meda,
Mylan and Verona. FJM has received personal fees from Adept, Afferent, Amgen,
AstraZeneca, Axon, Axon Communication, Boehringer Ingelheim, Clarion, ConCert,
Forest, Genentech, GlaxoSmithKline, Ikaria/Bellerophon, Informa, Janssen, Kadmon,
Lucid, Methodist Hospital, Novartis, Nycomed/Takeda, Pearl Therapeutics Inc.,
Pfizer, Prime, Roche, Sunovion, Theravance, Unity Biotechnology, Veracyte and
WebMD. He has received non-financial support from Biogen/Stromedix,
Boehringer Ingelheim, Centocor and Gilead and grants from the National Institutes
of Health. He has received personal fees for delivering CME programs for
Academic CME, American Thoracic Society, Annenberg, California Society for
Allergy and Immunology, CME Incite, Falco, Haymarket Communications,
Integritas, InThought, Miller Medical, National Association for Continuing
Education, Paradigm, Peer Voice, Potomac, UpToDate and Western
Society of Allergy and Immunology. He has received royalty fees from
Informa. He has spoken on behalf of AstraZeneca and Nycomed/Takeda.
He is currently a member of the GOLD Scientific Committee. JFD has
received personal fees from AstraZeneca, GlaxoSmithKline, Novartis,
Sunovion and Teva. PD, ES, CO, SSt, TF, MG and SD are employees of
Pearl Therapeutics, Inc., a member of the AstraZeneca Group.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was conducted in accordance with International Conference on
Harmonization guidelines, the Declaration of Helsinki, and the US Code of
Federal Regulations. The protocol, its amendments and patient informed
consent form were approved by an Independent Ethics Committee or
Institutional Review Board.
Author details
1Pearl Therapeutics Inc., 280 Headquarters Plaza, East Tower, 2nd Floor,
Morristown, NJ 07960, USA. 2Department of Medicine, University of Modena
and Reggio Emilia, NOCSAE, Modena, Italy. 3Clinical Research Institute of
Southern Oregon, Medford, OR, USA. 4Spartanburg Medical Research,
Spartanburg, NC, USA. 5American Health Research, Charlotte, NC, USA.
6Lungen Clinic Grosshansdorf, Airway Research Center North, Member of the
German Center for Lung Research (DZL), Grosshansdorf, Germany.
7Department of Medicine, Christian-Albrechts University Kiel, Kiel, MI, USA.
8Pulmonary Research Institute of Southeast Michigan, Farmington Hills, MI,
USA. 9Joan and Sanford I. Weill Department of Medicine, Weill Cornell
Medical College; New York-Presbyterian Hospital/Weill Cornell Medical
Center, New York, NY, USA. 10Department of Medicine, University of North
Carolina School of Medicine, Chapel Hill, NC, USA. 11Pearl Therapeutics Inc.,
Durham, NC, USA. 12Pearl Therapeutics Inc., Redwood City, CA, USA.
Received: 2 September 2016 Accepted: 13 December 2016
References
1. Cazzola M, Page CP, Calzetta L, Matera MG. Pharmacology and therapeutics
of bronchodilators. Pharmacol Rev. 2012;64:450–504.
2. Cooper CB, Barjaktarevic I. A new algorithm for the management of COPD.
Lancet Respir Med. 2015;3:266–8.
3. Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the
Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic
Obstructive Lung Diseases (GOLD) 2016 2016. [http://www.goldcopd.org].
Accessed 16 June 2016.
4. Yu AP, Guérin A, De Leon DP, Ramakrishnan K, Wu EQ, Mocarski M, et al.
Clinical and economic outcomes of multiple versus single long-acting
inhalers in COPD. Respir Med. 2011;105:1861–71.
5. Yu AP, Guerin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, et al.
Therapy persistence and adherence in patients with chronic obstructive
pulmonary disease: multiple versus single long-acting maintenance inhalers.
J Med Econ. 2011;14:486–96.
6. Calzetta L, Rogliani P, Matera MG, Cazzola M. A systematic review with
meta-analysis of dual bronchodilation with LAMA/LABA for the treatment of
stable COPD. Chest. 2016;149:1181–96.
7. Beier J, Kirsten AM, Mróz R, Segarra R, Chuecos F, Caracta C, et al. Efficacy and
safety of aclidinium bromide compared with placebo and tiotropium in patients
with moderate-to-severe chronic obstructive pulmonary disease: results from a
6-week, randomized, controlled Phase IIIb study. COPD. 2013;10:511–22.
8. Vehring R, Lechuga-Ballesteros D, Joshi V, Noga B, Dwivedi SK.
Cosuspensions of microcrystals and engineered microparticles for uniform
and efficient delivery of respiratory therapeutics from pressurized metered
dose inhalers. Langmuir. 2012;28:15015–23.
9. Fabbri LM, Kerwin EM, Spangenthal S, Ferguson GT, Rodriguez-Roisin R,
Pearle J, et al. Dose-response to inhaled glycopyrrolate delivered with a
novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in
patients with moderate-to-severe COPD. Respir Res. 2016;17:109.
10. Quinn D, Seale JP, Reisner C, Fischer T, Golden M, Fernandez C, et al. A
randomized study of formoterol fumarate in a porous particle metered-dose
inhaler in patients with moderate-to-severe COPD. Respir Med.
2014;108:1327–35.
11. Rennard S, Fogarty C, Reisner C, Fernandez C, Fischer T, Golden M,
et al. Randomized study of the safety, pharmacokinetics, and
bronchodilatory efficacy of a proprietary glycopyrronium metered-dose
inhaler in study patients with chronic obstructive pulmonary disease.
BMC Pulm Med. 2014;14:118.
12. Donohue JF. Minimal clinically important differences in COPD lung function.
COPD. 2005;2:111–24.
13. Sethi S, Fogarty C, Hanania NA, et al. Efficacy of formoterol fumarate
delivered by metered dose inhaler using Co-Suspension™ Delivery
Technology versus Foradil® Aerolizer® in moderate-to-severe COPD: a
randomized, dose-ranging study. Chronic Obstr Pulm Dis (Miami). 2017;4(1):
In press. doi:http://doi.org/10.15326/jcopdf.4.1.2016.0158.
14. Mahler DA, Kerwin E, Ayers T, FowlerTaylor A, Maitra S, Thach C, et al.
FLIGHT1 and FLIGHT2: efficacy and safety of QVA149 (indacaterol/
glycopyrrolate) versus its monocomponents and placebo in patients with
chronic obstructive pulmonary disease. Am J Respir Crit Care Med.
2015;192:1068–79.
15. Cazzola M, Calzetta L, Matera MG. β2 -adrenoceptor agonists: current and
future direction. Br J Pharmacol. 2011;163:4–17.
16. Cazzola M, Rogliani P, Matera MG. Aclidinium bromide/formoterol fumarate
fixed-dose combination for the treatment of chronic obstructive pulmonary
disease. Expert Opin Pharmacother. 2013;14:775–81.
17. Decramer M, Anzueto A, Kerwin E, Kaelin T, Richard N, Crater G, et al.
Efficacy and safety of umeclidinium plus vilanterol versus tiotropium,
vilanterol, or umeclidinium monotherapies over 24 weeks in patients with
chronic obstructive pulmonary disease: results from two multicentre, blinded,
randomised controlled trials. Lancet Respir Med. 2014;2:472–86.
18. Donohue JF, Maleki-Yazdi MR, Kilbride S, Mehta R, Kalberg C, Church A.
Efficacy and safety of once-daily umeclidinium/vilanterol 62.5/25 mcg in
COPD. Respir Med. 2013;107:1538–46.
19. Buhl R, Maltais F, Abrahams R, Bjermer L, Derom E, Ferguson G, et al.
Tiotropium and olodaterol fixed-dose combination versus mono-
components in COPD (GOLD 2–4). Eur Respir J. 2015;45:969–79.
20. Celli B, ZuWallack R, Wang S, Kesten S. Improvement in resting inspiratory
capacity and hyperinflation with tiotropium in COPD patients with
increased static lung volumes. Chest. 2003;124:1743–8.
21. Cohen JS, Miles MC, Donohue JF, Ohar JA. Dual therapy strategies for
COPD: the scientific rationale for LAMA + LABA. Int J Chron Obstruct
Pulmon Dis. 2016;11:785–97.
Reisner et al. Respiratory Research  (2017) 18:8 Page 12 of 13
22. Partridge MR, Karlsson N, Small IR. Patient insight into the impact of chronic
obstructive pulmonary disease in the morning: an internet survey. Curr Med
Res Opin. 2009;25:2043–8.
23. Miravitlles M, Worth H, Soler Cataluna JJ, Price D, De Benedetto F, Roche N,
et al. Observational study to characterise 24-hour COPD symptoms and
their relationship with patient-reported outcomes: results from the ASSESS
study. Respir Res. 2014;15:122.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Reisner et al. Respiratory Research  (2017) 18:8 Page 13 of 13
